4,901 trials
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
Primary: Cmax of AZD9291 — 242.5; 201.7 nM
Healthy
Primary: Maximum Mean Placebo-corrected QTcN Change From Baseline Between 1 to 24 Hours on Day 1 for the Combination Therapy — -0.47; -8.37 ms
Healthy Volunteers
Primary: Maximal Plasma Concentration (Cmax) of AGN-223575 — 0.186; 0.128; 0.114; NA Nanograms/Milliliters (ng/mL)
Viral Vaccines · Chikungunya Fever · Chikungunya Virus Infection
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants
Metastatic Colorectal Cancer
Primary: Maximum Observed Plasma Concentration (Cmax) of Irinotecan — 1570; 1570 ng/mL
Healthy
Primary: AUC0-∞ — 10600; 12400; 13600 nmol*h/L
Metastatic Pancreatic Cancer
Primary: Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer. — 1; 1; 2 participants
Healthy
Primary: Number of Healthy Subjects With AEs (Multiple Rising Dose Part) — 6; 5 participants
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Healthy Volunteers Bioavailability Study
Primary: Absolute Bioavailability — 62.1 % of bioavailability
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
Primary: AUC(0-72) of AZD9291 — 7403; 7345 nM*h
Pancreatic Carcinoma Non-resectable · Metastatic Pancreatic Cancer
Primary: To Determine the Dose Limiting Toxicities — 27 participants
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC 0-t) — 1490.0; 1273.0 h*ng/mL
COPD · Healthy Subjects
Primary: Adverse Events — 6; 3; 7; 2 Participants
Healthy Volunteers
Primary: Absolute Bioavailability of PBT2 (F%) — 15.936 percentage of absolute bioavailability